Felzartamab is under clinical development by Biogen and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate ...
Zanubrutinib is under clinical development by BeiGene and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase II drugs for Lupus Nephritis have a 50% phase transition success ...
The lupus nephritis market is poised for growth, driven by rising disease prevalence, advancements in therapeutics such as biologics and targeted therapies, and increased investment in R&D.
GlobalData on MSN11d
Palleon and Shanghai Henlius Biotech link on autoimmune therapyPalleon Pharmaceuticals and Shanghai Henlius Biotech have entered a licence agreement and partnership for the former’s ...
There is hope on the horizon for Lupus patients. A new multi-year clinical trial has commenced, testing whether a type of ...
The link between lupus and bipolar disorder is complex and can lead to misdiagnosis. Learn how to recognize the symptoms of ...
Nearly five years after establishing a U.S. headquarters in Montgomery County, a Canadian drugmaker is laying off dozens of ...
babul background This article will introduce you to the world's top 50 medical and health companies FDA approves first lupus nephritis treatment Merck's Keytruda was approved for a new indication and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback